Department of Obstetrics & Gynecology, National Taiwan University Hospital & College of Medicine, Taipei, Taiwan.
Regenerative Medicine Research Group, Institute of Cellular & System Medicine, National Health Research Institutes, Zhunan, Taiwan
Thorax. 2023 May;78(5):504-514. doi: 10.1136/thoraxjnl-2021-217928. Epub 2022 Apr 21.
Acute respiratory distress syndrome (ARDS) is a lethal complication of severe bacterial pneumonia due to the inability to dampen overexuberant immune responses without compromising pathogen clearance. Both of these processes involve tissue-resident and bone marrow (BM)-recruited macrophage (MΦ) populations which can be polarised to have divergent functions. Surprisingly, despite the known immunomodulatory properties of mesenchymal stem cells (MSCs), simultaneous interactions with tissue-resident and recruited BMMΦ populations are largely unexplored.
We assessed the therapeutic use of human placental MSCs (PMSCs) in severe bacterial pneumonia with elucidation of the roles of resident alveolar MΦs (AMΦs) and BMMΦs.
We developed a lethal, murine pneumonia model using intratracheal infection of a clinically relevant (KP) strain with subsequent intravenous human PMSC treatment. Pulmonary AMΦ and recruited BMMΦ analyses, histological evaluation, bacterial clearance and mice survival were assessed. To elucidate the role of resident AMΦs in improving outcome, we performed AMΦ depletion in the KPpneumonia model with intratracheal clodronate pretreatment.
Human PMSC treatment decreased tissue injury and improved survival of severe KPpneumonia mice by decreasing the presence and function of recruited M1 BMMΦ while preserving M2 AMΦs and enhancing their antibacterial functions. Interestingly, PMSC therapy failed to rescue AMΦ-depleted mice with KP pneumonia, and PMSC-secreted IL-1β was identified as critical in increasing AMΦ antibacterial activities to significantly improve pathogen clearance-especially bacteraemia-and survival.
Human PMSC treatment preferentially rescued resident M2 AMΦs over recruited M1 BMMΦs with overall M2 polarisation to improve KP-related ARDS survival.
急性呼吸窘迫综合征(ARDS)是严重细菌性肺炎的致命并发症,其原因是无法在不影响病原体清除的情况下抑制过度活跃的免疫反应。这两个过程都涉及组织驻留细胞和骨髓(BM)募集的巨噬细胞(MΦ)群体,这些细胞可以被极化以具有不同的功能。令人惊讶的是,尽管间充质干细胞(MSCs)具有已知的免疫调节特性,但同时与组织驻留细胞和募集的 BM 巨噬细胞(BMMΦ)群体的相互作用在很大程度上尚未得到探索。
我们评估了人胎盘间充质干细胞(PMSC)在严重细菌性肺炎中的治疗用途,并阐明了驻留肺泡巨噬细胞(AMΦ)和募集的 BMMΦ的作用。
我们使用临床相关(KP)菌株经气管内感染建立了致命性的小鼠肺炎模型,随后进行静脉内人 PMSC 治疗。评估了肺部 AMΦ和募集的 BMMΦ分析、组织学评估、细菌清除和小鼠生存情况。为了阐明驻留 AMΦ改善预后的作用,我们使用气管内氯膦酸盐预处理在 KP 肺炎模型中进行了 AMΦ耗竭。
人 PMSC 治疗通过减少募集的 M1 BMMΦ的存在和功能,同时保留 M2 AMΦ并增强其抗菌功能,降低了严重 KP 肺炎小鼠的组织损伤并提高了其生存率。有趣的是,PMSC 治疗未能挽救 KP 肺炎的 AMΦ耗竭小鼠,并且 PMSC 分泌的 IL-1β被鉴定为关键因子,可增强 AMΦ的抗菌活性,从而显著提高病原体清除率-特别是菌血症-和生存率。
人 PMSC 治疗优先挽救驻留的 M2 AMΦ,而不是募集的 M1 BMMΦ,整体上 M2 极化可改善与 KP 相关的 ARDS 生存率。